AMEX · Financial Statements
Actinium Pharmaceuticals, Inc. (ATNM) Financial Statements
$1.05
AMEX: ATNM
Market Cap $32.94M
Overview Financials Dividend Actinium Pharmaceuticals, Inc. most recently reported annual revenue of $0, net profit of $-34.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2021 2022 2023 2024 2025 Revenue $1.0M $1.0M $0 $0 $0 Operating Profit $-25.0M $-34.0M $-52.0M $-42.0M $-36.0M Net Profit $-25.0M $-33.0M $-49.0M $-38.0M $-34.0M EPS $-1.20 $-1.37 $-1.83 $-1.27 $-1.09 Op Margin -2182.2% -3311.1% -64098.8% — -40274.4%
Balance Sheet (USD)
Metric 2021 2022 2023 2024 2025 Total Assets $80.0M $114.0M $81.0M $77.0M $52.0M Total Liabilities $7.0M $48.0M $45.0M $44.0M $44.0M Cash $78.0M $109.0M $77.0M $73.0M $48.0M Borrowings $0 $3.0M $2.0M $2.0M $2.0M
Cash Flow (USD)
Metric 2021 2022 2023 2024 2025 Operating Cash Flow $-21.0M $9.0M $-47.0M $-33.0M $-25.0M Investing Cash Flow $0 $-1.0M $0 $0 $0 Financing Cash Flow $0 $0 $0 $0 $0 Net Cash Flow $14.0M $31.0M $-33.0M $-4.0M $-25.0M Free Cash Flow $-21.0M $8.0M $-47.0M $-33.0M $-25.0M
Valuation & Return Ratios
Metric Value PEG Ratio 0.01 EV / EBITDA -0.19 FCF Yield -70.90% Quick Ratio 4.08 Interest Coverage 0.00 Return 1Y -38.58% Return 3Y -86.91% Return 5Y -87.25%
Screens featuring this stock